Products

From Academic Kits to Platform Licensing

Four products, expanding margin over time. Start with research kits, grow into pharma platforms and IP royalties.

2026–27

Sivoro Start

The research kit

Development

Strain + scaffold kit for academic labs. Drop-in replacement for standard PDMS protocols. Includes engineered N. crassa strain, H-tree scaffold masters, growth media, and protocols.

✓ Engineered N. crassa strain ✓ H-tree scaffold masters ✓ Xylose growth media ✓ Protocol documentation ✓ Email support

Price point

$2,500 / kit

$500 reagent kit (20 assays)

Gross margin 70%

University research labs

2027–28

Sivoro Organ

The pharma platform

Planned 2027

Organ-on-chip integration targeting liver, gut, and blood-brain barrier models. Includes custom strain engineering and multi-year service contracts for pharma R&D teams.

✓ Organ-specific strain variants ✓ Co-culture integration ✓ Custom channel geometries ✓ Dedicated technical support ✓ Annual service contract

Price point

$50k–150k platform

$10k–30k annual service

Gross margin 60%

Pharma R&D

2028–29

Sivoro License

The IP stream

Planned 2028

License Sivoro strain and valve IP to existing PDMS chip manufacturers. Non-exclusive royalties of 5–7%; exclusive arrangements at 10–12% plus upfront. Pure IP — lowest cost to deliver.

✓ Strain IP license ✓ Optogenetic valve IP ✓ Transfer package ✓ Field of use restrictions ✓ Sub-licensing rights

Price point

5–10% royalty

Exclusive: 10–12% + upfront

Gross margin 90%

Microfluidics OEMs

2029+

Sivoro Dx

The diagnostic device

Planned 2029+

Diagnostic device for point-of-care testing. Starting as RUO (research use only) for academic and pharma R&D, then following 510(k) pathway for clinical applications.

✓ RUO initial release ✓ 510(k) pathway ✓ CLIA-waived target ✓ Point-of-care format ✓ Per-assay economics

Price point

Per-assay pricing

Subscription panel model

Gross margin 75%+

Clinical / RUO

Market Opportunity

TAM Expansion

Each product tier unlocks a larger addressable market, compounding total opportunity.

$0.5BM Academic microfluidics

$2B Organ-on-chip by 2030

$5B PDMS replacement licensing

The $25B total microfluidics market is our ceiling — but Sivoro's unique living-chip position enables entry across all three segments sequentially.

Business Model

Three revenue streams, expanding margin over time

Stream 1

Academic Kits

2026–2028

70%

Sivoro Start kit: strain + scaffold + protocols. Recurring revenue from media replacements and strain upgrades.

$2,500 starter · $500 reagent kit (20 assays)

Stream 2

Pharma Platforms

2027–2030

60%

Sivoro Organ platform with organ-chip integration. Custom strain engineering + service contracts.

$50k–150k platform · $10k–30k annual service

Stream 3

IP Licensing

2028+

90%

License strain + valve IP to PDMS manufacturers. Pure IP — lowest cost to deliver.

Non-exclusive: 5–7% royalty · Exclusive: 10–12% + upfront

Year 3 Revenue Mix

40% Kits

30% Platforms

30% Licensing